Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NP91

UPID:
S6A20_HUMAN

ALTERNATIVE NAMES:
Sodium/imino-acid transporter 1; Solute carrier family 6 member 20; Transporter rB21A homolog

ALTERNATIVE UPACC:
Q9NP91; A1A4F2; O75590; Q8TF10; Q9NPQ2; Q9NQ77

BACKGROUND:
Sodium- and chloride-dependent transporter XTRP3, known alternatively as Sodium/imino-acid transporter 1 and Solute carrier family 6 member 20, mediates the uptake of imino acids and N-methylated amino acids, crucial for brain proline and glycine homeostasis. This transporter's function affects NMDAR currents, indicating its significant role in neurotransmission.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Sodium- and chloride-dependent transporter XTRP3 could open doors to potential therapeutic strategies for treating Hyperglycinuria and Iminoglycinuria. Its direct involvement in these diseases suggests that modulating XTRP3 activity could offer new avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.